PCIBR&D•globenewswire•
PCI Biotech announces discontinuation of development of the PCL technology and evaluation of future operations
Sentiment:Negative (-70)
Summary
Oslo (Norway), 18 August 2025 – PCI Biotech Holding ASA (PCI Biotech, OSE:PCIB) today announces the discontinuation of development of the photochemical lysis (PCL) technology for viral vector manufacturing.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 18, 2025 by globenewswire